Navigation Links
Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
Date:8/18/2010

BOULDER, Colo., Aug. 18 /PRNewswire/ -- Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH).  The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).  Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

"Development of radiological/nuclear countermeasures to treat ARS is a high priority research area for NIAID," said George (Joe) Cox, Ph.D., Company President and Principal Investigator for the grant.  "We are delighted to receive a grant award from NIAID to conduct research with our long-acting IL-11 analog in ARS."  

Bone marrow is one of the most sensitive tissues to radiation damage and impaired production of blood cells is one of the first clinical signs of excessive radiation exposure, often resulting in death.  IL-11 is a protein that stimulates bone marrow cells to divide and differentiate into platelets.  Recent studies indicate that IL-11 can mitigate some of the hematopoietic and gastrointestinal complications of radiation exposure and improve survival in animal models of ARS.  IL-11 has a short half-life in humans, which necessitates daily dosing, and may not optimize therapeutic benefits of the protein for patients.  A long-acting IL-11 analog that does not require frequent dosing could provide significant treatment advantages in a nuclear emergency setting.

The NIH SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs.  

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases.

Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties.  There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company.  These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

www.bolderbio.com


'/>"/>
SOURCE Bolder BioTechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
2. Kun Run Biotechnology Announces That They Have Obtained the Manufacturing Approval for Entecavir from the China State Food and Drug Administration
3. Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer
4. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
5. Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
6. Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News
7. Americas Pharmaceutical Research and Biotechnology Companies Lead the Charge Toward Longer, Healthier Lives for Americans
8. PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract
9. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
10. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
11. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest ... is the first of its kind in the ... tattoos through advanced laser treatment. The physician-owned and ... Suncoast by storm with its revitalizing ... and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... India , February 5, 2016 ... a new market research report "Fetal (Labor & Delivery) ... & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, ... published by MarketsandMarkets, This report studies the global market ... market is estimated at USD 6.28 Billion in 2015 ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ... "Global Obstetrics Partnering 2010-2016: Deal trends, ... their offering. --> Research and ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... President George H. Van Allen have signed a joint enrollment and degree completion ... seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... The American ... technology, such water may be safer than regular municipal or well water. The recent ... radio host Sharon Kleyne, could go a long way toward increasing public acceptance of ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
(Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... Columbia University Men’s Soccer Career Development event in New York City on Thursday, ... Commisso, Chairman and CEO of Mediacom, (both alumnus of the varsity Columbia soccer ...
Breaking Medicine News(10 mins):